This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Mitsubishi Tanabe Pharma Corporation
Drug Names(s): MP-513, Tenelia (Japan)
Description: MP-513 is a selective non-cyanopyrroridine dipeptidyl peptidase IV (DPP-IV) inhibitor. DPP-IV is an enzyme that breaks down glucagon-like peptide-1 (GLP-1). GLP-1 binds to receptors on pancreatic beta cells stimulating the release of the hormone insulin. GLP-1 also reduces the secretion of glucagon, a hormone produced by the pancreas that stimulates the liver to convert glycogen to glucose thus increasing blood sugar levels. By delaying the degradation of GLP-1, DPP-IV inhibitors extend the action of insulin while also suppressing the release of glucagon.
MP-513 has a low excretion by the kidneys and long duration of action, which the company hopes to help it differentiate from other DPP-IV inhibitors.
Mitsubishi Tanabe and Handok
In September 2011, Mitsubishi Tanabe licensed out MP-513 to Handok Pharmaceuticals for the treatment of type 2 diabetes in Korea.
Mitsubishi Tanabe and Daiichi Sankyo
In March 2012, Mitsubishi Tanabe and Daiichi Sankyo agreed to form a strategic sales alliance to conduct joint sales activities for MP-513 (teneligliptin) and TA-7284 (canagliflozin) in Japan for the treatment of type 2 diabetes mellitus.
Partners: Daiichi Sankyo Co., Ltd. Handok Pharmaceuticals, Inc.
Additional information available to subscribers only: